Veracyte
VCYT
43.16
-1.49
-3.34%
Veracyte
US · VCYT
#2330 by market cap
Listed 1970
43.16
-1.49
-3.34%
Live - 5344 symbols - heartbeat 338s ago
· 2026-10-08 06:26
Pre-market
42.82
-0.79%
After-hours
43.16
0.00%
Overnight
43.00
-0.37%
- Market cap
- 3.47B
- P/E (TTM)i
- 30.83
- P/Bi
- 2.50
- EPSi
- 0.82
- Div yieldi
- 0.00%
- 52W posi
- 44%
Reader sentiment
Are you bullish or bearish on VCYT?
Anonymous reader poll. Unscientific, not investment advice.
About Veracyte
Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.
- Founded
- 2006
- CEO
- Mr. Marc A. Stapley
- Employees
- 755
- Headquarters
- South San Francisco, California, United States of America
- Fiscal year end
- 12-31
- Website
- veracyte.com
Company profile
- Exchange
- US
- Symbol
- VCYT
- Market-cap rank
- #2330
- Listing date
- 1970-01-01
- Market cap
- 3.47B
- Float cap
- 3.45B
- Shares out
- 80.39M
- Float shares
- 79.88M
Sectors & themes
Quote time 2026-10-08 06:26:05 · For reference only, not investment advice and not tailored to your situation.